Universal Ibogaine (FRA:JC4) Net Income From Continuing Operations : €-1.53 Mil (TTM As of Jan. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Universal Ibogaine Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Universal Ibogaine's net income from continuing operations for the three months ended in Jan. 2025 was €-0.20 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jan. 2025 was €-1.53 Mil.

Universal Ibogaine Net Income From Continuing Operations Historical Data

The historical data trend for Universal Ibogaine's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Net Income From Continuing Operations Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

Jul24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-0.08

-0.19

-7.98

-1.64

-1.38

Universal Ibogaine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-0.15	-0.59	-0.51	-0.23	-0.20

Universal Ibogaine Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.53 Mil.

Universal Ibogaine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (FRA:JC4) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

IBOGF:USA IBO:Canada

Address

C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2

Website

https://www.universalibogaine.com

Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.

Universal Ibogaine Headlines

No Headlines